Dynamic Glucose Enhanced (DGE) CEST imaging at 3T: from phantom to patient with brain metastases
Yulun Wu1, Sophie H.A.E. Derks1,2,3, Tobias Wood4, Astrid A.M. van der Veldt1,2, Marion Smits1, and Esther A.H. Warnert1
1Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands, 2Department of Medical Oncology, Erasmus MC, Rotterdam, Netherlands, 3Department of Neurology, Erasmus MC, Rotterdam, Netherlands, 4Centre for Neuroimaging Science, King's College London, London, United Kingdom
To develop detection of glucose contrast enhancement (GCE) with CEST for assessing brain metastases in clinical setting, here we performed a phantom study, scanned 10 healthy volunteers and one patient with brain metastases at 3T. We acquired dynamic GCE at 1.2 and 2 ppm for dynamic B0 correction and applied principle component analysis (PCA) to perform noise reduction, after which we compared the resulting GCE at both offsets. The developed pipeline resulted in GCE of ~5% in tumor and -5 to 0.05% in healthy tissues after glucose infusion.
This abstract and the presentation materials are available to members only;
a login is required.